New data on patient satisfaction with sebetralstat treatment presented at medical conference

Data on a recently approved medicine for HAE, called Ekterly (sebetralstat) has been presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and Western Society of Allergy, Asthma and Immunology (WSAAI) 63rd Annual Scientific Session.

The data demonstrated that as an oral, on-demand medicine, sebetralstat reduced barriers to treatment, enabling patients to take medication early, which was associated with an improved treatment response. Overall, the data highlight the potential of sebetralstat to help treat more attacks, earlier, with sustained efficacy and high satisfaction.

Ben Palleiko, CEO of KalVista, said: “The data presented at AAAAI and WSAAI reinforce the importance of treating HAE attacks early, which is consistently associated with improved outcomes. In the KONFIDENT-S open-label extension, we are observing sustained effectiveness and high patient satisfaction with repeated use of sebetralstat, along with meaningful changes in treatment behavior, including treating the majority of attacks, early intervention, and preference for an oral option. Together, these findings support our belief that Ekterly has the potential to transform how HAE is managed and deliver sustained real-world benefit for people living with HAE.”

(Source: KalVista)